Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts

View Full Paper
Ask AI
Bookmark
Share

Authors

SASafa Saadat AfridiASAl-Aman Shaukat

Discussion

Loading...

Member takes

Overview

Observational analysis shows high cytokine release syndrome rates in DLBCL patients receiving CAR-T therapy, indicating varied biomarker responses across constructs.

Key Points

  • Cytokine release syndrome occurred at high rates across all CAR-T constructs in DLBCL patients, with no significant differences observed.
  • In post-infusion cohorts, elevated ferritin levels were noted, highlighting varied inflammatory responses linked to treatment.
  • Propensity score matching was utilized to balance patient characteristics across FDA-approved CAR-T therapies in the analysis.
  • Findings emphasize the need for tailored monitoring and management strategies based on individual inflammatory responses.

Cite This Study

Afridi et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e274https://doi.org/10.1182/blood-2025-5504
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma2025
  2. 2Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.2026
  3. 3Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices2025 · 1 citations
  4. 4Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis2025 · 1 citations
  5. 5A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium2025 · 1 citations